We are monitoring the impact of COVID-19 & Recession alarm on Europe Bladder Cancer Therapeutics Market Get in touch with us for detailed analysis Know More
Share on

Europe Bladder Cancer Therapeutics Market Research Report – Segmented By Type, Treatment & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) – Industry Size, Share, Trends, Growth & Forecasts (2022 to 2027)

Published: January, 2022
ID: 1087
Pages: 138

Europe Bladder Cancer Therapeutics Market Size & Growth (2022 to 2027)

The size of the Bladder Cancer Therapeutics market in Europe is expected to reach USD 83.83 million by 2027 from USD 65.81 million in 2022, growing at a CAGR of 4.96% during the forecast period 2022 to 2027.

Bladder cancer is aroused due to malignancy of urinary bladder lining with epithelial cells. The bladder is an organ present at the lower part of the abdomen and stores urine. Over developing of these epithelial cells results in blabber cancer and it can be of many types such as transitional cell carcinoma, squamous cell carcinoma, and adenocarcinoma. At the present number of therapies have been evolved for the management of bladder cancers include chemotherapies, immunotherapies, surgeries, radiation therapies, and other therapies.

Increasing technological advancements with regards to bladder cancer, government initiatives, and the presence of developed healthcare infrastructure are driving the growth of the bladder cancer therapeutics market in Europe. However, the high cost of advanced bladder cancer therapies and stringent regulatory pathways are restraining the growth of the bladder cancer therapeutics market in Europe.

This research report on the Europe Bladder Cancer Therapeutics Market has been segmented and sub-segmented into the following categories

By Type:

  • Transitional Cell Bladder Cancer
  • Non-Muscle Invasive/Superficial Bladder Cancer
  • Invasive Bladder Cancer
  • Squamous Cell Bladder Cancer
  • Adenocarcinoma of the Bladder
  • Rare Bladder Cancers

By Treatment:

  • Surgery
  • Chemotherapy
  • Immunotherapy
  • Radiation Therapy
  • Intravesical Therapy

By Country:

  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands
  • Turkey
  • Czech Republic
  • Rest of Europe

Promising companies leading the Europe Bladder Cancer Therapeutics Market profiled in this report are Sanofi S.A. (France), Novartis AG (Switzerland), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Eli Lilly and Company (U.S.), AstraZeneca plc (U.K.), Bristol-Myers Squibb (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Celgene Corporation (U.S.).

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods  

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Type                        

                                5.1.1 Transitional Cell Bladder Cancer    

                                5.1.2 Non Muscle Invasive/Superficial Bladder Cancer     

                                5.1.3 Invasive Bladder Cancer    

                                5.1.4 Squamous Cell Bladder Cancer       

                                5.1.5 Adenocarcinoma of the Bladder    

                                5.1.6 Rare Bladder Cancers         

                5.2 By Treatment                            

                                5.2.1 Surgery    

                                                5.2.1.1 Transurethral Bladder Tumor Resection (TURBT)

                                                5.2.1.2 Cystectomy

                                                5.2.1.3 Urinary Diversion

                                5.2.2 Chemotherapy     

                                5.2.3 Immunotherapy   

                                5.2.4 Radiation Therapy

                                5.2.5 Intravesical Therapy           

6. Geographical Analysis                                              

                6.1 Europe                         

                                6.1.1 Introduction           

                                6.1.2 U.K             

                                6.1.3 Spain         

                                6.1.4 Germany 

                                6.1.5 Italy           

                                6.1.6 France      

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Sanofi S.A. (France)                 

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Novartis AG (Switzerland)                    

                9.3 Pfizer Inc. (U.S.)                       

                9.4 GlaxoSmithKline plc (U.K.)                   

                9.5 Eli Lilly and Company (U.S.)                 

                9.6 AstraZeneca plc (U.K.)                           

                9.7 Bristol-Myers Squibb (U.S.)                 

                9.9 F. Hoffmann-La Roche Ltd. (Switzerland)                       

                9.10 Celgene Corporation (U.S.)               

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures      

                10.4 New Product Launches                       

11.Expert Opinions                                         

                11.1 Market Outlook                     

                11.2 Investment Opportunities                 

Appendix                                           

                a) List of Tables                

                b) List of Figures               

  1. Europe Bladder Cancer Therapeutics Market By Region, From 2022 - 2027 (USD Million)
  2. Europe Bladder Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  3. Europe Transitional Cell Bladder Cancer Market By Region, From 2022 - 2027 (USD Million)
  4. Europe Non Muscle Invasive/Superficial Bladder Cancer Market By Region, From 2022 - 2027 (USD Million)
  5. Europe Invasive Bladder Cancer Market By Region, From 2022 - 2027 (USD Million)
  6. Europe Squamous Cell Bladder Cancer Market By Region, From 2022 - 2027 (USD Million)
  7. Europe Adenocarcinoma of the Bladder Market By Region, From 2022 - 2027 (USD Million)
  8. Europe Rare Bladder Cancers Market By Region, From 2022 - 2027 (USD Million)
  9. Europe Bladder Cancer Therapeutics Market By Treatment, From 2022 - 2027 (USD Million)
  10. Europe Bladder Cancer Surgery Market By Region, From 2022 - 2027 (USD Million)
  11. Europe Bladder Cancer Chemotherapy Market By Region, From 2022 - 2027 (USD Million)
  12. Europe Bladder Cancer Immunotherapy Market By Region, From 2022 - 2027 (USD Million)
  13. Europe Bladder Cancer Radiation Therapy Market By Region, From 2022 - 2027 (USD Million)
  14. Europe Bladder Cancer Intravesical Therapy Market By Region, From 2022 - 2027 (USD Million)
  15. U.K. Bladder Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  16. U.K. Bladder Cancer Therapeutics Market By Treatment, From 2022 - 2027 (USD Million)
  17. Germany Bladder Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  18. Germany Bladder Cancer Therapeutics Market By Treatment, From 2022 - 2027 (USD Million)
  19. France Bladder Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  20. France Bladder Cancer Therapeutics Market By Treatment, From 2022 - 2027 (USD Million)
  21. Italy Bladder Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  22. Italy Bladder Cancer Therapeutics Market By Treatment, From 2022 - 2027 (USD Million)
  23. Spain Bladder Cancer Therapeutics Market By Type, From 2022 - 2027 (USD Million)
  24. Spain Bladder Cancer Therapeutics Market By Treatment, From 2022 - 2027 (USD Million)
  25. Europe Bladder Cancer Surgery Market By Type, From 2022 - 2027 (USD Million)
  26. Europe Transurethral Bladder Tumor Resection (TURBT) Market By Region, From 2022 - 2027 (USD Million)
  27. Europe Bladder Cancer Cystectomy Market By Region, From 2022 - 2027 (USD Million)
  28. Europe Bladder Cancer Urinary Diversion Market By Region, From 2022 - 2027 (USD Million)
  29. U.K. Bladder Cancer Surgery Market By Type, From 2022 - 2027 (USD Million)
  30. Germany Bladder Cancer Surgery Market By Type, From 2022 - 2027 (USD Million)
  31. France Bladder Cancer Surgery Market By Type, From 2022 - 2027 (USD Million)
  32. Italy Bladder Cancer Surgery Market By Type, From 2022 - 2027 (USD Million)
  33. Spain Bladder Cancer Surgery Market By Type, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample